文献速递基础与转化研究临床试验与 GCP

造血干细胞基因治疗用于胱氨酸病

Hematopoietic Stem-Cell Gene Therapy for Cystinosis.
PubMed 文献 · N Engl J Med · 2026-01-01

本研究为1-2期开放标签持续临床试验,评估自体CD34+细胞经慢病毒载体导入CTNS cDNA(CTNS-RD-04)治疗胱氨酸病的安全性与疗效。6例20至46岁患者接受治疗并随访29至63个月,不良事件多与清髓方案及基础病一致,除载体拷贝数最低的患者外白细胞胱氨酸水平较基线下降。

要点

  • CTNS-RD-04在6例胱氨酸病患者中安全性可接受,不良事件多与清髓及基础病相关。
  • 所有患者实现持续多克隆造血重建,24个月载体拷贝数为0.51至2.67拷贝/二倍体基因组。
  • 除载体拷贝数最低的患者外,治疗后白细胞胱氨酸水平较基线下降。

核心结论

  • 在这项小样本研究中,CTNS-RD-04的不良事件主要与清髓方案及基础病特征一致,且治疗后白细胞胱氨酸水平下降。

研究设计与样本

  • 1-2期开放标签持续临床试验,评估自体CD34+细胞经慢病毒载体携带CTNS cDNA(CTNS-RD-04)治疗胱氨酸病。
  • 共6例20至46岁患者接受CTNS-RD-04并随访29至63个月。

主要发现

  • CTNS-RD-04剂量范围为3.63×10^6至9.59×10^6 CD34+细胞/千克体重,载体拷贝数为0.59至2.91拷贝/二倍体基因组。
  • 所有患者均实现持续且高度多克隆的造血重建,24个月时载体拷贝数为0.51至2.67拷贝/二倍体基因组。
  • 共发生217例不良事件,大多为轻至中度,主要与操作及基础病一致,未观察到单克隆扩增证据。
  • 除载体拷贝数最低的第4例患者外,其余患者白细胞胱氨酸水平均较基线下降。

临床怎么用

  • 该研究为小样本初步评估,尚不能将CTNS-RD-04作为胱氨酸病常规治疗推荐。

局限性

  • 研究样本量小(6例),为开放标签、非对照设计,疗效需更大规模对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cystinosis is a multisystemic lysosomal storage disorder caused by pathogenic variants in CTNS, the gene encoding cystinosin, a lysosomal transmembrane cystine transporter. In patients with cystinosis, cystine accumulates within lysosomes in all organs. The cystine-depleting agent cysteamine delays but does not prevent disease progression. METHODS: In this phase 1-2, open-label, ongoing clinical study, we performed a preliminary assessment of CTNS-RD-04, which consists of autologous CD34+ cells transduced with lentiviral vectors carrying CTNS complementary DNA, in patients with cystinosis. The primary end points were the safety and the side-effect profiles of CTNS-RD-04. Secondary end points were measures of efficacy, including white-cell cystine levels and cystine storage depletion. Oral cysteamine was withdrawn before CTNS-RD-04 infusion, and cysteamine eyedrops were withdrawn 1 month after myeloablation. RESULTS: Six participants (20 to 46 years of age) received CTNS-RD-04 and were followed for 29 to 63 months. CTNS-RD-04 doses ranged from 3.63×106 to 9.59×106 CD34+ cells per kilogram of body weight, and vector copy numbers ranged from 0.59 to 2.91 copies per diploid genome. All the patients had sustained and highly polyclonal hematopoietic reconstitution; vector copy numbers at 24 months ranged from 0.51 to 2.67 copies per diploid genome. A total of 217 adverse events occurred, most of which were mild or moderate in severity and largely consistent with the procedures and underlying disease. No evidence of monoclonal expansion was noted. White-cell cystine levels decreased from baseline except in Patient 4, who had the lowest vector copy number. CONCLUSIONS: In this small study, CTNS-RD-04, an ex vivo gene therapy for cystinosis, had adverse effects that were largely consistent with the myeloablative regimen and underlying disease profile. White-cell cystine levels decreased after therapy. (Funded by the California Institute for Regenerative Medicine and others; ClinicalTrials.gov number, NCT03897361.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Barshop BA, Ball ED, Benador N, et al. Hematopoietic Stem-Cell Gene Therapy for Cystinosis. N Engl J Med. 2026. PMID: 41707137. doi:10.1056/NEJMoa2506431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。